Treatment of adult T-cell leukaemia/lymphoma: Is the virus a target?

Current Opinion in Infectious Diseases

Volumn 28, Issue 6, 2015, Pages 583-588

  Cook, Lucy B ^a,b   Taylor, Graham P ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

adult T cell leukaemia lymphoma; human T lymphotropic virus type 1; interferon; mLSG15; zidovudine

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BENDAMUSTINE; BIOLOGICAL MARKER; CANCER VACCINE; CHEMOKINE RECEPTOR CCR4; HISTONE DEACETYLASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PRALATREXATE; VALPROIC ACID; ZIDOVUDINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL THERAPY; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CLONE; DRUG EFFICACY; EX VIVO STUDY; HUMAN; HUMAN T-LYMPHOTROPIC VIRUS 1; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LEUKEMIA RELAPSE; LYMPHOCYTOSIS; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVIEW; T CELL LEUKEMIA; T CELL LYMPHOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; DRUG EFFECTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HTLV-I INFECTIONS; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MORTALITY; MULTIMODALITY CANCER THERAPY; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNOTHERAPY; LEUKEMIA-LYMPHOMA, ADULT T-CELL; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84947023028     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000207     Document Type: Review

References (47)

1. Yamaguchi K, Watanabe T. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int J Hematol 2002; 76 (Suppl 2):240-245.
2. Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: A nationwide prospective study in Japan. Blood 2010; 116:1211-1219.
3. Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: A randomized phase II study. Br J Haematol 2015; 169:672-682.
4. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007; 25: 5458-5464.
5. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001; 113:375-382.
6. Seiki M, Eddy R, Shows TB, Yoshida M. Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells. Nature 1984; 309:640-642.
7. Gillet NA, Malani N, Melamed A, et al. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood 2011; 117:3113-3122.
8. Melamed A, Laydon DJ, Gillet NA, et al. Genome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infection. PLoS Pathog 2013; 9:e1003271.
9. Cook LB, Melamed A, Niederer H, et al. The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphoma. Blood 2014; 123:3925-3931.
10. Laydon DJ, Melamed A, Sim A, et al. Quantification of HTLV-1 clonality and TCR diversity. PLoS Comput Biol 2014; 10:e1003646.
11. Bangham CR, Cook LB, Melamed A. HTLV-1 clonality in adult T-cell leukaemia and non-malignant HTLV-1 infection. Semin Cancer Biol 2014; 26:89-98.
12. Tsukasaki K, Tsushima H, Yamamura M, et al. Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood 1997; 89:948-956.
13. Sakashita A, Hattori T, Miller CW, et al. Mutations of the p53 gene in adult Tcell leukemia. Blood 1992; 79:477-480.
14. Tawara M, Hogerzeil SJ, Yamada Y, et al. Impact of p53 aberration on the progression of adult T-cell Leukemia/Lymphoma. Cancer Lett 2006; 234:249-255.
15. Hatta Y, Koeffler HP. Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL). Leukemia 2002; 16:1069-1085.
16. Pancewicz J, Taylor JM, Datta A, et al. Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci U S A 2010; 107:16619-16624.
17. Nakagawa M, Schmitz R, Xiao W, et al. Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J Exp Med 2014; 211:2497-2505.
18. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991; 79:428-437.
19. Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. WHO Press; 2008.
20. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting. J Clin Oncol 2009; 27:453-459.
21. Shimoyama M, Ota K, Kikuchi M, et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol 1988; 6:128-141.
22. Shimoyama M, Ota K, Kikuchi M, et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. J Clin Oncol 1988; 6:1088-1097.
23. Tobinai K, Shimoyama M, Minato K, et al. Japan Clinical Oncology Group phase II trial of second-generation LSG4 protocol in aggressive T-and Blymphoma: A new predictive model for T-and B-lymphoma. Proc Am Soc Clin Oncol 1994; 13:378.
24. Gill PS, HarringtonWJr, Kaplan MH, et al. Treatment of adult T-cell leukemialymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995; 332:1744-1748.
25. Hermine O, Bouscary D, Gessain A, et al. Brief report: Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995; 332:1749-1751.
26. Matutes E, Taylor GP, Cavenagh J, et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 2001; 113:779-784.
27. Hermine O, Allard I, Lé vy V, et al. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 2002; 3:276-282.
28. Ramos JC, Ruiz P Jr, Ratner L, et al. IRF-4 and c-Rel expression in antiviralresistant adult T-cell leukemia/lymphoma. Blood 2007; 109:3060-3068.
29. Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 2010; 28:4177-4183.
30. Pimentel A, Reis I, Chapman-Fredricks JR, Ramos JC. Clinical features and outcome of adult T-cell leukemia/lymphoma: University of Miami experience. Retrovirology 2014; 11:O1.
31. Fields PA, Taylor GP. 'Antivirals' in the treatment of adult T cell leukaemialymphoma (ATLL). Curr Hematol Malig Rep 2012; 7:267-275.
32. Hodson A, Demontis M-A, Cook L, et al. Haematological and molecular responses in patients with chronic ATLL treated with zidovudine and interferon-a. Retrovirology 2014; 11:O5.
33. Datta A, Bellon M, Sinha-Datta U, et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 2006; 108:1021-1029.
34. Kinpara S, Kijiyama M, Takamori A, et al. Interferon-a (IFN-a) suppresses HTLV-1 gene expression and cell cycling, while IFN-a combined with zidovudin induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology 2013; 10:52.
35. Ceesay MM, Matutes E, Taylor GP, et al. Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/ lymphoma (ATLL). Leuk Res 2012; 36:857-861.
36. Chen J, Pise-Masison CA, Shih JH, et al. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. Blood 2013; 121:2029-2037.
37. Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol 2002; (19 Suppl):S27-S32.
38. Araya N, Sato T, Ando H, et al. HTLV-1 induces a Th1-like state in CD4CCR4 T cells. J Clin Invest 2014; 124:3431-3442.
39. Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: A nationwide retrospective study. Blood 2010; 116:1369-1376.
40. Suehiro Y, Hasegawa A, Iino T, et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/ lymphoma in a pilot study. Br J Haematol 2015; 169:356-367.
41. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferonalpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999; 93:278-283.
42. El-Sabban M, Nasr R, Dbaibo G, et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood 2000; 96:2849-2855.
43. Nasr R, Rosenwald A, El-Sabban ME, et al. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 2003; 101:4576-4582.
44. Kchour G, Tarhini M, Kooshyar MM, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009; 113:6528-6532.
45. Suarez F, Marcais A, Ghez David, et al. Arsenic trioxyde in the treatment of HTLV1 associated ATLL. Retrovirology 2011; 8:A59.
46. Achachi A, Florins A, Gillet N, et al. Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo. Proc Natl Acad Sci U S A 2005; 102:10309-10314.
47. Afonso PV, Mekaouche M, Mortreux F, et al. Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. Blood 2010; 116:3802-3808.